Evotec (NASDAQ:EVO) Price Target Raised to $5.00

Evotec (NASDAQ:EVO) had its price target increased by HC Wainwright from $4.00 to $5.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target points to a potential upside of 181.69% from the stock’s previous close.

Several other brokerages have also recently issued reports on EVO. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday, July 15th. Weiss Ratings downgraded Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. Finally, Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $3.50.

Evotec Stock Performance

Shares of EVO stock opened at $1.77 on Friday. The stock’s fifty day moving average is $1.62 and its two-hundred day moving average is $2.49. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33. Evotec has a fifty-two week low of $1.33 and a fifty-two week high of $3.87.

Institutional Investors Weigh In On Evotec

An institutional investor recently raised its stake in Evotec stock. Optiver Holding B.V. boosted its holdings in shares of Evotec AG (NASDAQ:EVO) by 598.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 283,576 shares of the company’s stock after acquiring an additional 242,973 shares during the quarter. Optiver Holding B.V. owned about 0.08% of Evotec worth $709,000 at the end of the most recent quarter. Institutional investors own 5.81% of the company’s stock.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Q3 adjusted EBITDA loss narrowed to €1.6 million, while reported revenue of €164.9 million and an EPS loss of $0.11 beat analyst estimates. The company also reaffirmed its FY2026 guidance. Evotec Q3 and nine-month results
• Positive Sentiment: Evotec reported 24% growth in D&PD base-business net sales and won a Vertex manufacturing mandate, supporting the case for commercial momentum. Vertex manufacturing mandate
• Neutral Sentiment: Management said restructuring is progressing, but the Redmond expansion may create a gap before added capacity contributes revenue. The timing and pace of the ramp could affect near-term performance. Redmond expansion revenue gap
• Negative Sentiment: Nine-month revenue fell to €465.0 million from €477.4 million at constant exchange rates, and adjusted EBITDA remained negative. Evotec also tempered and pushed out medium-term goals, including lowering its 2030 revenue target. Evotec cuts 2030 revenue target
• Negative Sentiment: RBC maintained a cautious view and cut its price target to €5, adding to concerns about the reduced longer-term outlook. RBC target and Vertex mandate

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.